1 2	Sex Differences in Colonic Mucosal Microbiome of Irritable Bowel Syndrome Patients Compared to Healthy Controls
3	Swapna Mahurkar-Joshi <sup>1-4</sup> . Simer Shera <sup>4</sup> . Jennifer Labus <sup>1-4</sup> . Tien S.
4	Dong <sup>1-4</sup> , Jonathan P. Jacobs <sup>1-4</sup> , Lin Chang <sup>1-4</sup>
6	Affiliations
7	
8 9	1. Vatche and Tamar Manoukian Division of Digestive Diseases, University of California, Los Angeles, Los Angeles, California.
10 11 12 13 14	<ol> <li>G. Oppenneimer Center for Neurobiology of Stress and Resilience, Los Angeles, California</li> <li>UCLA Goodman-Luskin Microbiome Center, Los Angeles, California.</li> <li>University of California, Los Angeles, Los Angeles, California.</li> </ol>
15 16	Conflicts of Interest: None of the authors have any conflicts of interest to disclose.
17 18 19 20 21	<b>Author contribution:</b> SMJ: design of study, analysis, writing, and editing. SS: writing and editing. JL: analysis and editing. TSD: data acquisition and editing. JPJ: data acquisition and editing. LC: design of study, data acquisition, analysis, writing, and funding. SCORE group: writing/editing, data acquisition.
22	Tables and Figures: Tables - 2, Figures - 2
23	<u>Supplementary Materials</u> : Supplementary Table – 1
24	Abstract word count: 260
25 26	Manuscript Word Count: 2086
27	Funding: NIH P50 DK64539, U54 DK123755, R21 DK104078, UL1TR0001881, VA
28	IK2CX001717 (JPJ)
29	Corresponding author:
30	Swapna Mahurkar-Joshi
31	swapnajoshi@mednet.ucla.edu
32 33	
34	

## 35 Abstract

30	
37	Background: Irritable bowel syndrome (IBS) is a female-predominant disorder of brain-gut
38	interactions. Our previous study on colonic mucosal microbiota demonstrated significant
39	differences between IBS bowel habit subtypes and showed that gut microbiota is associated
40	with abdominal pain in IBS patients. However, there is no consensus on sex-related differences
41	in mucosal microbiota in IBS compared to healthy controls (HC). We aimed to identify sex-
42	related differences in the mucosal microbes associated with IBS.
43	
44	Methods: Sigmoid mucosal biopsies were obtained from 97 Rome+ IBS patients and 54 healthy
45	controls (HC). Mucosal microbiome was characterized using 16S rRNA sequencing and
46	analyzed and general linear models were used to test group differences between IBS diagnosis
47	and sex. Sex-specific relationships between mucosal microbiome and IBS symptoms were
48	assessed using sparse partial least squares (sPLS) regression.
49	
50	Results: Beta diversity was significantly different between men and women overall (p=.03) but
51	not within IBS or HC. IBS women showed lower abundance of Catenibacterium and
52	Ruminoclstridium_9 and increased abundance of Bacteroides, Escherichia/Shigella,
53	Lachnoclostridium and Ruminococcaceae compared to men with IBS (p<0.05). However,
54	healthy women had a lower abundance of six distinct genera compared to healthy men. In
55	women, higher IBS symptoms were associated with an increased abundance of bacteria
56	including prevotella_9, and paraprevotella, however, in men, IBS symptoms were associated
57	with increased abundances of genera such as Dialister. Interestingly, increased abundance of
58	Desulfovibrio was associated with higher symptoms in women but lower symptoms in men.
59	

- 60 Conclusion: There are distinct sex-related differences in the mucosal microbiome between IBS
- and healthy participants supporting the importance of studying sex-specific mechanisms in IBS
- 62 pathophysiology.

- \_ \_

- . .

- .

## 79 Introduction

80 Irritable bowel syndrome (IBS) is a female-predominant disorder of altered bidirectional gutbrain interactions characterized by chronic abdominal pain and altered bowel habits.<sup>1, 2</sup> It is a 81 82 widely prevalent condition affecting up to 11% of the general population.<sup>3</sup> IBS is associated with microbial dysbiosis and studies suggest a key role for the gut microbiome in its pathogenesis.<sup>4-7</sup> 83 84 Most studies investigating relationships between the gut microbiome and IBS focused on fecal samples due to their noninvasive collection methods.<sup>8</sup> While these studies have provided 85 86 valuable insight, fecal samples do not capture critical microbial interactions occurring at the 87 mucosal surface. Emerging evidence suggests that mucosal microbiota, or microbiota in close 88 proximity to the gut epithelium layer, immune cells and enteric nerves, may play a pivotal role in 89 IBS.<sup>9, 10</sup> Our earlier work identified significant IBS bowel habit differences in mucosal microbiota. 90 such as constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and IBS with 91 mixed bowel habits (IBS-M), and reported an association between gut microbiota composition and abdominal pain in IBS patients.<sup>11</sup> These findings emphasize the importance of considering 92 93 mucosal microbiota when investigating IBS.

94

The influence of sex on gut microbiome has not been well studied in IBS, despite IBS being 95 more common in women compared to men and women reporting a higher symptom severity.<sup>12-14</sup> 96 97 We recently found sex differences in fecal microbial composition in IBS participants but not 98 healthy controls (HC). Prevotella was the main difference between men and women with IBS and it negatively correlated with IBS severity<sup>15</sup>. However, sex-specific differences in mucosal 99 100 microbiota and their association with IBS have not been investigated. Therefore, this study 101 aimed to identify 1) sex differences in mucosal microbial abundances overall and within IBS and 102 HC groups and 2) mucosal microbiota associated with IBS symptom severity in women and 103 men.

#### 105 Methods

#### 106 Study participants

107 The study population included 18-55 year-old men and women with IBS and HC recruited by 108 community advertisement as described previously.<sup>11</sup> IBS and bowel habit subtypes were diagnosed based on medical history, physical exam, and Rome criteria.<sup>2</sup> Subtypes included 109 110 IBS-C, IBS-D, IBS-M, and unsubtyped IBS (IBS-U). HC had no personal or family history of any 111 pain conditions. Additional exclusion criteria for all participants included the following: celiac 112 disease, inflammatory bowel disease, or other gastrointestinal (GI) illness which could explain 113 IBS symptoms, active psychiatric illness in the past six months according to the Diagnostic and 114 Statistical Manual of Mental Disorders, 4th Edition, Text Revision (MINI International 115 Neuropsychiatric Interview).<sup>16</sup> current substance dependence or abuse, smoking more than 1/2 116 pack per day, and use of corticosteroids in past six months, antibiotics or narcotics in past three 117 months, or probiotics in past one month before the procedure. Participants were not excluded if 118 they were on proton pump inhibitors. During the procedure, two patients were reported using 119 pantoprazole or omeprazole. The University of California, Los Angeles Institutional Review 120 Board approved the study, and participants signed a written informed consent before the study. 121 Participants were compensated.

122

#### 123 Questionnaires

Patients were assessed for overall severity, abdominal pain, and bloating within the prior week with numerical rating scales from 0 (no pain) to 20 (most intense symptoms imaginable) using our Bowel Symptom Questionnaire (BSQ).<sup>17</sup> The Hospital Anxiety and Depression Scale (HAD) was used to measure current anxiety and depression symptoms.<sup>18</sup> The IBS-SSS assesses the severity and frequency of abdominal pain, distention, bowel dysfunction, and global well-being in IBS.<sup>19</sup> Summed scores between 75 and 175 represent mild disease, 175-300 moderate

- 130 disease, and >300 severe disease. Each questionnaire is validated and widely used, with
- 131 instructions for how to complete and score them.
- 132
- 133 Sample Collection
- 134 During flexible sigmoidoscopy, mucosal biopsies were collected at 30 centimeters from the anal
- 135 verge. Biopsies were snap-frozen in liquid nitrogen and stored at -80C. Participants were asked
- to withhold from using aspirin and nonsteroidal anti-inflammatory drugs 72 hours before the
- 137 procedure.
- 138
- 139 Dietary Assessments
- 140 An institution-developed Diet Checklist was used with the intention to represent diet(s) that best
- 141 reflect what individuals consume regularly.<sup>20</sup> Options included standard or modified American,
- 142 Mediterranean, vegetarian, vegan, dairy-free, gluten-free, and/or low fermentable
- 143 oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diets. Each diet was
- 144 classified as either standard or restrictive depending on the elimination of certain food groups by
- 145 choice. A food frequency questionnaire (FFQ) and diet diary were used for a specific subset of
- 146 patients to validate the diet checklist.<sup>20</sup>
- 147
- 148 Microbiome Analysis
- 149 DNA Extraction and Sequencing
- 150 Bacterial DNA was extracted from the biopsies using the PowerSoil DNA Isolation Kit (MO BIO
- 151 Laboratories) with bead beating. 16S rRNA gene sequence libraries were generated using the
- 152 V4 hypervariable region and amplified with the 515F and 806R primers. Libraries were
- 153 sequenced on Illumina HiSeq 2500 platform (Life Sciences, Branford, CT).
- 154

The DADA2 pipeline in R was used to process the raw reads.<sup>20</sup> Silva v132 reference database 155 was used to eliminate chimeras and assign taxonomy. Samples were rarefied to even depth for 156 157 calculation of alpha diversity measures using the function, "rarefy even depth." The read depth 158 was 29,709 (SD: 33,526.25) and rarefied to 538 counts. To avoid data loss, alpha diversity was 159 calculated using unrarefied data and beta diversity using relative abundance. Amplicon 160 sequence variant (ASV) data was applomerated at the genus level to study shifts in microbial 161 abundance. ASVs are exact sequence variants compared with operational taxonomic units, or 162 clusters of reads with 97% similarity. 163 164 **Statistical Analysis** 

165

166 All statistical analyses were performed using R software.<sup>21</sup> Sex differences in alpha diversity 167 and beta diversity overall and within IBS and HC were assessed using a general linear models. 168 The model included age, body mass index (BMI), race, intake of a restrictive diet, and 169 sequencing batch as covariates. Frequent category imputation for categorical data and mean 170 values for continuous data were used to address missing data on covariates. To maximize 171 power, the restrictive diet variable was imputed for missing data when used as a covariate. 172 Chao1 and Shannon's index were used as metrics for alpha diversity as described previously<sup>11</sup>. 173 Briefly, beta diversity was evaluated using DEICODE, a form of Aitchison distance that is robust 174 to high levels of sparsity, implemented in a QIIME environment. Adonis, a permutational 175 analysis of variance, was used to test for associations with demographic characteristics and 176 clinical factors.

177

Group comparisons for clinical and demographic characteristics were performed using t-test or
chi-square tests. Genus-level data were extracted and filtered to include genera present in
atleast 10% samples. Data were transformed using centered log-ratio (CLR) transformation.

181	Generalized linear (GLM) with sex as an independent variable, microbial abundance as an
182	independent variable covarying for age, BMI, race, intake of restrictive diet, and technical
183	sequencing batch as covariates, was used to evaluate differences in microbial abundances
184	between females and males. We also evaluated sex differences within IBS and HC groups
185	within the framework of a general linear model with microbial abundance dependent variable.
186	Bowel habit was used as a covariate when analyzing group differences within IBS. Results were
187	corrected for multiple comparisons using a false discovery rate (FDR) and an FDR<.25 was
188	considered significant.
189	
190	Sparse partial least squares (sPLS) regressions were performed to reduce dimensionality while
191	analyzing correlations between clinical variables and microbiota data in multivariate analysis. <sup>22</sup>
192	Data were residualized for sequencing batch, diet, and bowel habit subtypes. The "tune.spls"
193	function from 'mixOmics' package was used to select tuning parameters and the first two
194	components were used for analysis. <sup>23</sup>
195	
196	
197	Results
198	Demographic and clinical characteristics
199	We analyzed sex differences in colonic mucosal microbiome of 151 participants (97 Rome+ IBS
200	patients and 54 healthy controls). Table 1 shows the demographic characteristics of male and
201	female IBS and HC participants. IBS women were younger compared to IBS men (mean
202	[standard deviation] = 29.4 [10.8] vs 36.3 [10.3], p=0.003), and there were differences in the
203	bowel habit subtypes with more men with IBS-D subtype compared to IBS-C (Chi-squared =
204	14.66, p=0.02). There were no other significant differences in demographic characteristics

- 205 between sexes within both groups. Additionally, IBS symptom scores were comparable between
- 206 men and women with IBS (**Table 1**).

207

208	Mucosal Microbiota in Men Compared to Women with IBS and Healthy Controls
209	Microbial analysis revealed significant differences in beta diversity between men and women in
210	the overall study population (r <sup>2</sup> =0.014, p=0.03). There were no significant differences in alpha
211	diversity. Although no genera were significant at an FDR<.25, we found nominal significance
212	(p<0.05) for differences between sexes. Genus-level differences were found in the abundance
213	of five microbes between women and men in the overall participant population. Three genera
214	(Prevotella_9, Catenibacterium, and Ruminiclostridium_9) were less abundant and two
215	(Tyzzerella and Escherichia/Shigella) were more abundant in women compared to men (Table
216	2). Within the IBS group, women showed an altered abundance of five genera including a lower
217	abundance of Catenibacterium, and Ruminoclstridium_9, and an increased abundance of
218	Bacteroides, Escherichia/Shigella, and Lachnoclostridium compared to men (Figure 1A, Table
219	2). However, within the HC group, women had a lower abundance of six genera compared to
220	men (Figure 1B, Table 2). The sex-associated microbes within IBS were distinct compared to
221	HC.
222	
223	Sex-related differences in IBS symptoms
224	Multivariate analysis to evaluate microbial species associated with IBS symptoms identified 20
225	IBS-symptom-associated genera in men and women. In women, higher symptoms were
226	associated with an increase in abundance of bacterial genera including Paraprevotella,
227	Megasphera, Clostridium_sensu_stricto_1, Desulphovibrio, Candidatus_Arthromonitus and
228	Catenibacterium (Figure 2A). In men, however, increased symptoms were associated with an

increase of *Staphylococcus*, *Finegoldia*, and *Dialister* (Figure 2B). Increased abundances of

230 *Prevotella\_7 and Prevotella\_9* were associated with higher symptoms in both sexes, but

- stronger correlations were observed in women. Interestingly, an increased abundance of
- 232 Desulfovibrio was associated with higher symptom severity in women but lower in men.

233

#### 234 Discussion

The colonic mucosal microbiome is grossly understudied compared to the fecal microbiome in IBS. Despite growing evidence of sex differences in symptoms and physiologic alterations in IBS, there was previously no data on sex differences in mucosal microbiome in IBS. This is the first study to investigate sex-related differences in mucosal microbiota in IBS and HC. The important findings of our study are that 1) IBS is associated with distinct sex-related differences compared to HC and 2) distinct microbial genera are associated with the severity of IBS symptoms in women compared to men.

242

243 The distinct sex differences we identified in the IBS mucosal microbiome compared to HC and 244 their correlation with IBS symptom severity support the importance of these differences in the 245 pathophysiology of IBS. Increased abundance of bacterial genera including Lachnoclostridium 246 in IBS women, which is associated with an immune inflamed gene expression profile suggests its potential role in modulating the immune microenvironment contributing to IBS symptoms.<sup>24</sup> 247 248 Interestingly, our study identified mucosal-associated *Prevotella* as less abundant in healthy 249 women than healthy men but this was not seen in IBS. Decreased fecal abundance of 250 Prevotella in fecal samples has been previously reported in healthy women compared to men. 251 <sup>25, 26</sup> In a different and larger cohort of IBS and HC participants, we also found that *Prevotella* 252 was the main driver of sex differences in stool samples of IBS with lower in abundance in 253 women compared to men, but this was not seen in HC. The lower fecal abundance of Prevotella 254 was associated with increased IBS symptom severity, while increased mucosal abundance 255 correlated with increased IBS severity in both women and men. Our differing results support prior studies that mucosal and fecal microbiota differ significantly from one another.<sup>27, 28</sup> Of note, 256 257 Prevotella is a highly heterogeneous genus and some species can be beneficial, while others that can be pathogenic.<sup>29</sup> Due to the resolution of 16S sequencing, we could not determine 258

which species of *Prevotella* were associated with sex differences in the stool and mucosalsamples.

261

262 Our study identified other sex-specific associations of IBS symptoms with bacterial genera. 263 Increased *Desulfovibrio* was associated with lower symptoms in men but higher symptoms in 264 women. Desulphovibrio is a sulfate-reducing bacteria (SRB) known for its direct association with increased hydrogen sulfide production and high-fat diet-induced colitis.<sup>24</sup> One potential 265 266 mechanism linking microbes to sex-specific disease association may be through sex hormones. 267 For example, studies suggest that estrogen affects the expression of toll-like receptors (TLRs), 268 which induce a pro-inflammatory environment that facilitates the translocation of bacteria into 269 the lamina propria thereby amplifying the pro-inflammatory responses.<sup>30</sup> These sexually 270 dimorphic effects of microbes on IBS symptoms emphasize the necessity for sex-specific 271 investigations into the role of microbiota composition in IBS. 272 273 Some of the bacteria we observed as differentially abundant between sexes were also reported 274 in the context of various diseases and health (**Supplementary Table 1**). Similarly, 275 Clostridium sensu stricto 1, an opportunistic pathogen, which was associated with increased 276 symptoms in women but not men in our study, is also reported to be increased in women with chronic fatigue syndrome (CFS),<sup>31</sup> which is a known comorbidity of IBS, predominantly women. 277 278 Another genus, Catenibacterium, which was less abundant in the colonic mucosa of IBS women 279 compared to men, was found to be lower in IBS compared to healthy controls. It is a butyrateproducing bacteria known to improve intestinal barrier function,<sup>32</sup> and has also been reported to 280 be less abundant in women compared to men,<sup>33</sup> (**Supplementary Table 1**). 281

282

There are some limitations to this study. We only sampled the sigmoid colonic mucosa butevidence suggests that there are significant differences in mucosal microbiota along the

285	intestinal tract. <sup>25</sup> While our sample size is lower than fecal microbiome studies, our study has
286	the largest mucosal microbiome sample in the field so far. Metagenomic sequencing was limited
287	to only the specific DNA regions covered by 16S rRNA sequencing. Using shotgun
288	metagenomic sequencing instead would allow us to identify all genomic DNA in the sample.
289	
290	In conclusion, our study that sex moderates differences in microbial abundances in colonic
291	mucosal tissue and their relationship to IBS symptom severity. The findings indicate the
292	importance of investigating sex-specific mechanisms in-depth and they may differ in the stool vs
293	intestinal mucosa. Further research is warranted to delineate the specific roles of the microbes
294	identified in the pathophysiology of IBS.

## 296 References

- 297 1. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016.
- 298 2. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain
- 299 Interaction. Gastroenterology 2016;150:1257-61.
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a
   meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-721 e4.
- Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet
   Gastroenterol Hepatol 2016;1:133-146.
- Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med 2017;376:2566 2578.
- Ghaffari P, Shoaie S, Nielsen LK. Irritable bowel syndrome and microbiome; Switching
   from conventional diagnosis and therapies to personalized interventions. J Transl Med
   2022;20:173.
- 309 7. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both
- 310 duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients.
- 311 World J Gastroenterol 2009;15:2887-92.
- Juge N. Relationship between mucosa-associated gut microbiota and human diseases.
   Biochem Soc Trans 2022;50:1225-1236.
- 314 9. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: how do communities
  315 of bacterial symbionts become established in our intestine? Nat Immunol 2004;5:569-73.
- 316 10. Tropini C, Earle KA, Huang KC, et al. The Gut Microbiome: Connecting Spatial
- 317 Organization to Function. Cell Host Microbe 2017;21:433-442.
- 318 11. Choo C, Mahurkar-Joshi S, Dong TS, et al. Colonic mucosal microbiota is associated
- 319 with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome.
- 320 Am J Physiol Gastrointest Liver Physiol 2022;323:G134-G143.

- 321 12. Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers
  322 2016;2:16014.
- 323 13. Ford AC, Sperber AD, Corsetti M, et al. Irritable bowel syndrome. Lancet
  324 2020;396:1675-1688.
- Lee SY, Kim JH, Sung IK, et al. Irritable bowel syndrome is more common in women
  regardless of the menstrual phase: a Rome II-based survey. J Korean Med Sci
  2007;22:851-4.
- 328 15. Dong TS, Peters K, Gupta A, et al. Prevotella Is Associated with Sex-Based Differences
   329 in Irritable Bowel Syndrome. Gastroenterology 2024.
- 330 16. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric

331 Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric

interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22-33;quiz 34-57.

- 333 17. Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation induces rectal
- 334 hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997;112:55-
- 335 63.
- 336 18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr
  337 Scand 1983;67:361-70.
- Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple
  method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther
  1997;11:395-402.
- 20. Lenhart A, Dong T, Joshi S, et al. Effect of Exclusion Diets on Symptom Severity and the
  Gut Microbiota in Patients with Irritable Bowel Syndrome. Clin Gastroenterol Hepatol
  2021.
- Team RC. R: A language and environment for statistical computing. Vienna, Austria: R
  Foundation for Statistical Computing, 2020.

- 346 22. Lê Cao K-A, González I. and Déjean S. integrOmics: an R package to unravel
- relationships between two omics data sets. Bioinformatics. Bioinformatics 2009;25:28552856.
- Rohart F, Gautier B, Singh A, et al. mixOmics: An R package for 'omics feature selection
  and multiple data integration. PLoS Comput Biol 2017;13:e1005752.
- 351 24. Yilmaz E YA, Dwidar M.E., Geiger J.L., Koyfman S, Chan T.A., Silver N, .
- 352 Lachnoclostridium and Immune Inflamed Gene Expression Signature Association in
- Head & Neck Cancers. International Journal of Radiation Oncology, Biology, Physics
  2022;112:E37.
- 355 25. Mueller S, Saunier K, Hanisch C, et al. Differences in fecal microbiota in different
  356 European study populations in relation to age, gender, and country: a cross-sectional
  357 study. Appl Environ Microbiol 2006;72:1027-33.
- 358 26. Takagi T, Naito Y, Inoue R, et al. Differences in gut microbiota associated with age, sex,
  359 and stool consistency in healthy Japanese subjects. J Gastroenterol 2019;54:53-63.
- 360 27. Ringel Y, Maharshak N, Ringel-Kulka T, et al. High throughput sequencing reveals
- 361 distinct microbial populations within the mucosal and luminal niches in healthy
- individuals. Gut Microbes 2015;6:173-81.
- 363 28. Zoetendal EG, von Wright A, Vilpponen-Salmela T, et al. Mucosa-associated bacteria in
  364 the human gastrointestinal tract are uniformly distributed along the colon and differ from
- the community recovered from feces. Appl Environ Microbiol 2002;68:3401-7.
- 366 29. Precup G, Vodnar DC. Gut Prevotella as a possible biomarker of diet and its eubiotic
- 367 versus dysbiotic roles: a comprehensive literature review. Br J Nutr 2019;122:131-140.
- 368 30. Garcia-Gomez E, Gonzalez-Pedrajo B, Camacho-Arroyo I. Role of sex steroid hormones
   in bacterial-host interactions. Biomed Res Int 2013;2013:928290.
- 370 31. Wallis A, Butt H, Ball M, et al. Support for the Microgenderome: Associations in a Human
  371 Clinical Population. Sci Rep 2016;6:19171.

- 372 32. Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrate- and methane-producing
- 373 microorganisms in patients with Irritable Bowel Syndrome. Sci Rep 2015;5:12693.
- 374 33. Santos-Marcos JA, Haro C, Vega-Rojas A, et al. Sex Differences in the Gut Microbiota
- 375 as Potential Determinants of Gender Predisposition to Disease. Mol Nutr Food Res
- 376 2019;63:e1800870.
- 377
- 378

## 379 FIGURE LEGENDS

#### 380 Figure 1. Microbial Genera Altered in Women Compared to Men in IBS Patients and

- 381 Healthy Controls. At the genus level, five microbes were different between women compared
- to men in IBS and six microbes were different between women compared to men in healthy
- 383 controls (p<0.05).
- 384

#### 385 Figure 2. Sex-specific Correlations between Mucosal Microbial Genera and Clinical

## 386 Symptoms of IBS Patients

- 387 The correlation heatmaps show the microbes selected by sparse partial least squared analysis
- 388 within men and women at genus level that were positively or negatively correlated with IBS
- 389 symptoms including abdominal pain, bloating, and overall symptom severity. X-axis represents
- 390 IBS symptom severity measures and Y-axis represents microbes. Red color indicates a positive

391 correlation and blue indicates a negative correlation.

# 393 Supplementary Table 1. IBS and Sex-associated Microbiota Reported in Literature

- 394 Supplementary Table 1 shows a list of studies that investigated microbes that were found to be
- 395 associated with sex within IBS or healthy controls in this study.

396

397

399 Table 1: Demographic and Clinical Characteristics of the Study Popul
--

	F (N=63)	M (N=34)	Chi-Square/ t value/Estimates	P-value
IBS (N=97)				
Age [Mean(SD)]	29.4 (10.8)	36.3 (10.3)	3.06	0.003
BMI [Mean(SD)]	25.1 (5)	25.9 (3.8)	0.75	0.457
Bowel Habit Subtype			14.66\$	0.002
IBS-C (N=27)	19 (30%)	8 (24%)		
IBS-D (N=37)	20 (32%)	17 (50%)		
IBS-M (N=23)	21 (33%)	2 (6%)		
IBS-U (N=10)	3 (5%)	7 (20%)		
Ethnicity			2.04\$	0.361
Hispanic (N=19)	14 (22%)	5 (15%)		
Non-Hispanic (N=76)	47 (75%)	29 (85%)		
Not Available (N=2)	2 (3%)	0 (0%)		
Race			4.11 <sup>\$</sup>	0.250
Asian (N=10)	6 (9%)	4 (12%)		
Black (N=20)	15 (24%)	5 (15%)		
Multiracial (N=16)	7 (11%)	9 (26%)		
White (N=48)	32 (51%)	16 (47%)		
Not Available (N=3)	3 (5%)	0 (0%)		
IBS Symptoms				
HAD Anxiety (0-21) <sup>18</sup>	6.8 (4.3)	7.7 (5)	-0.89#	0.36
HAD Depression (0-21) <sup>18</sup>	3 (3.3)	4.1 (3.8)	-1.11#	0.14
IBS-SSS (0-500) <sup>19</sup>	214.7 (84.5)	208.4 (96.8)	6.36#	0.79
Overall Symptom Severity (0-20) <sup>17</sup>	8.4 (4.3)	10.3 (4.2)	-1.89#	0.04
Abdominal Pain (0-20) <sup>17</sup>	8.4 (4)	10.1 (4.1)	-1.68#	0.06
Bloating (0-20) <sup>17</sup>	10.7 (4.6)	10.7 (5.1)	0.02#	0.98
VSI Score (0-75) <sup>17</sup>	35.9 (16.2)	33.9 (16.6)	1.96#	0.57
Healthy controls (N=54)	F (N=26)	M (N=28)		
Age [Mean(SD)]	30.4 (9.6)	33.6 (12.1)	1.07	0.29
BMI [Mean(SD)]	25.3 (4.2)	25.4 (3.3)	0.02	0.98
Ethnicity			1.27\$	0.259
Hispanic (N=12)	8 (31%)	4 (14%)		
Non-Hispanic (N=42)	18 (69%)	24 (86%)		
Race			2.33 <sup>\$</sup>	0.507
Asian (N=5)	3 (11%)	2 (7%)		
Black (N=10)	5 (19%)	5 (18%)		
Multiracial (N=7)	5 (19%)	2 (7%)		
White (N=29)	12 (46%)	17 (61%)		
Not Available (N=3)	1 (4%)	2 (7%)		

- 401 Table 1 shows the demographic and clinical characteristics of men and women with IBS and
- 402 health controls; <sup>\$</sup>, chi-square statistic; <sup>#</sup>, Estimate (beta); IBS-C, irritable bowel syndrome with
- 403 constipation; IBS-D, irritable bowel syndrome with diarrhea; IBS-M, irritable bowel syndrome
- 404 with mixed pattern; IBS-U, irritable bowel syndrome unsubtyped. IBS-SSS, IBS Severity Scoring
- 405 System. HAD, Hospital Anxiety and Depression Scale.
- 406
- 407

Genus	Phylum	Participants	Estimate	P.value	FDR
Prevotella_9	Bacteroidetes	All	-1.17	0.039	0.58
Escherichia/Shigella	Proteobacteria	All	0.84	0.027	0.51
Tyzzerella	Firmicutes	All	0.62	0.014	0.50
Ruminiclostridium_9	Firmicutes	All	-0.43	0.020	0.50
Catenibacterium	Firmicutes	All	-0.74	0.018	0.50
Bacteroides	Bacteroidetes	IBS	0.63	0.049	0.63
Escherichia/Shigella	Proteobacteria	IBS	1.16	0.035	0.63
Lachnoclostridium	Firmicutes	IBS	0.94	0.016	0.59
Ruminiclostridium 9	Firmicutes	IBS	-0.60	0.015	0.59
Catenibacterium	Firmicutes	IBS	-0.87	0.045	0.63
Prevotella 9	Bacteroidetes	Healthy controls	-2.43	0.020	0.28
Butyricicoccus	Firmicutes	Healthy controls	-1.21	0.008	0.20
Ruminiclostridium 5	Firmicutes	Healthy controls	-1.06	0.022	0.28
Blautia	Firmicutes	Healthy controls	-1.37	0.019	0.28
Agathobacter	Firmicutes	Healthy controls	-1.70	0.007	0.20
Lachnospiraceae ND3007 group	Firmicutes	Healthy controls	-1.33	0.006	0.20

## 408 Table 2: Sex-associated Microbial Genera in IBS Patients and Healthy Controls.

409

410 Table 2 shows microbial genera altered in women compared to men within the entire study

411 population, IBS, and healthy control groups. Negative estimates indicate a lower abundance,

412 and positive estimates indicate a higher abundance of genera in women compared to men.

# 413 Figure 1: Microbial Genera Altered in Women Compared to Men in IBS Patients and

## 414 Healthy Controls.

415



# 420 Figure 2: Sex-specific Correlations between Mucosal Microbial Genera and Clinical

421

**Symptoms of IBS Patients** 



